Tarsus Pharmaceuticals is a commercial-stage biopharma company focused on eye care, best known for XDEMVY (lotilaner ophthalmic solution), the first FDA-approved treatment for Demodex blepharitis. Its pipeline targets other ocular diseases where parasites, inflammation or related mechanisms play a role. The company sells primarily through eye-care professionals rather than as a broad primary-care drug franchise.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 102.7 | — | -20.3 | — |
| Q3 2025 | 118.7 | — | -12.6 | — |
| Q4 2025 | 151.7 | — | -8.4 | — |
| Q1 2026 | 162.1 | — | -7 | — |
| Q2 2026 | 173.9 | 69.4% | -18.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Mechanics Bancorp (MCHB), IDEAYA Biosciences, Inc. (IDYA), Pulse Biosciences, Inc. (PLSE), Slide Insurance Holdings, Inc. (SLDE), Seacoast Banking Corporation of Florida (SBCF), Golub Capital BDC, Inc. (GBDC)